HS
TRVI icon

HighVista Strategies’s Trevi Therapeutics TRVI Stock Holding History

HighVista Strategies’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Sell
53,033
-492
-0.9% -$7.16K 0.23% 116
2026
Q1 		$639K Sell
53,525
-52,634
-50% -$589K 0.18% 143
2025
Q4 		$1.33M Buy
+106,159
New +$1.23M 0.34% 77

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

HighVista Strategies's TRVI Position: Q2 2026 in Review

HighVista Strategies reduced its Trevi Therapeutics (TRVI) stake by 0.92% in Q2 2026, selling an estimated $7.16K and leaving 53,033 shares worth $989K. The position accounts for 0.23% of the portfolio, ranked #116.

HighVista Strategies first reported a position in TRVI in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.33M in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • HighVista Strategies held 53,033 shares of Trevi Therapeutics worth $989K as of Q2 2026.
  • HighVista Strategies sold 492 Trevi Therapeutics shares in Q2 2026, an estimated $7.16K.
  • Trevi Therapeutics made up 0.23% of HighVista Strategies's portfolio in Q2 2026, its #116 holding.
  • HighVista Strategies first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • HighVista Strategies's Trevi Therapeutics position peaked at $1.33M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.